Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers

Abstract Radiotherapy (RT) for prostate cancer increases the risk of bladder cancer. The genomic landscape of bladder cancer following RT for prostate cancer and its differentiation from bladder cancers that develop without a history of pelvic RT remains unclear. We examined gene mutations in bladde...

Full description

Saved in:
Bibliographic Details
Main Authors: Shogo Adomi, Kazuko Sakai, Yurie Kura, Marco A De Velasco, Saizo Fujimoto, Shingo Toyoda, Mamoru Hashimoto, Mitsuhisa Nishimoto, Eri Banno, Yoshitaka Saito, Koichi Sugimoto, Yujiro Hayashi, Takafumi Minami, Kazuhiro Yoshimura, Hirotsugu Uemura, Kazuto Nishio, Kazutoshi Fujita
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-025-05149-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849769261906526208
author Shogo Adomi
Kazuko Sakai
Yurie Kura
Marco A De Velasco
Saizo Fujimoto
Shingo Toyoda
Mamoru Hashimoto
Mitsuhisa Nishimoto
Eri Banno
Yoshitaka Saito
Koichi Sugimoto
Yujiro Hayashi
Takafumi Minami
Kazuhiro Yoshimura
Hirotsugu Uemura
Kazuto Nishio
Kazutoshi Fujita
author_facet Shogo Adomi
Kazuko Sakai
Yurie Kura
Marco A De Velasco
Saizo Fujimoto
Shingo Toyoda
Mamoru Hashimoto
Mitsuhisa Nishimoto
Eri Banno
Yoshitaka Saito
Koichi Sugimoto
Yujiro Hayashi
Takafumi Minami
Kazuhiro Yoshimura
Hirotsugu Uemura
Kazuto Nishio
Kazutoshi Fujita
author_sort Shogo Adomi
collection DOAJ
description Abstract Radiotherapy (RT) for prostate cancer increases the risk of bladder cancer. The genomic landscape of bladder cancer following RT for prostate cancer and its differentiation from bladder cancers that develop without a history of pelvic RT remains unclear. We examined gene mutations in bladder cancers that developed following RT and those that developed without prior RT. Fourteen patients who developed primary bladder cancer following brachytherapy were categorized into radiation-associated bladder tumor (RA-BT) group, whereas 33 patients diagnosed with primary bladder cancer without a history of pelvic RT were classified into the bladder tumor (BT) group. The frequency of TERT promoter mutations was 35.7% and 63.6% in the RA-BT and BT groups, respectively (p = 0.112). Among the other characteristic mutations, FGFR3 and TP53 were frequently observed in both groups (FGFR3: RA-BT vs. BT, 14.3 vs. 42.4%; TP53: RA-BT vs. BT, 50 vs. 33.3%). Rare mutations in bladder cancer were more frequently observed in the RA-BT group, including ADGRB3 (28.6%), CBL (21.4%), TGM7 (21.4%), and BTK (14.3%). There were significantly more C → T substitutions in the RA-BT group than in the BT group. In our study, the genetic mutations in the RA-BT group had distinct features from those in the BT group.
format Article
id doaj-art-308bf00f10e34a5587d3b67ef38505da
institution DOAJ
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-308bf00f10e34a5587d3b67ef38505da2025-08-20T03:03:28ZengNature PortfolioScientific Reports2045-23222025-07-0115111110.1038/s41598-025-05149-zComparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancersShogo Adomi0Kazuko Sakai1Yurie Kura2Marco A De Velasco3Saizo Fujimoto4Shingo Toyoda5Mamoru Hashimoto6Mitsuhisa Nishimoto7Eri Banno8Yoshitaka Saito9Koichi Sugimoto10Yujiro Hayashi11Takafumi Minami12Kazuhiro Yoshimura13Hirotsugu Uemura14Kazuto Nishio15Kazutoshi Fujita16Department of Urology, Faculty of Medicine, Kindai UniversityDepartment of Genome Biology, Faculty of Medicine, Kindai UniversityDepartment of Genome Biology, Faculty of Medicine, Kindai UniversityDepartment of Genome Biology, Faculty of Medicine, Kindai UniversityDepartment of Urology, Faculty of Medicine, Kindai UniversityDepartment of Urology, Faculty of Medicine, Kindai UniversityDepartment of Urology, Faculty of Medicine, Kindai UniversityDepartment of Urology, Osaka Minami Medical CenterDepartment of Urology, Mimihara General HospitalDepartment of Urology, Mimihara General HospitalDepartment of Urology, Faculty of Medicine, Kindai UniversityDepartment of Urology, Johns Hopkins University Faculty of MedicineDepartment of Urology, Faculty of Medicine, Kindai UniversityDepartment of Urology, Faculty of Medicine, Kindai UniversityDepartment of Urology, Faculty of Medicine, Kindai UniversityDepartment of Genome Biology, Faculty of Medicine, Kindai UniversityDepartment of Urology, Faculty of Medicine, Kindai UniversityAbstract Radiotherapy (RT) for prostate cancer increases the risk of bladder cancer. The genomic landscape of bladder cancer following RT for prostate cancer and its differentiation from bladder cancers that develop without a history of pelvic RT remains unclear. We examined gene mutations in bladder cancers that developed following RT and those that developed without prior RT. Fourteen patients who developed primary bladder cancer following brachytherapy were categorized into radiation-associated bladder tumor (RA-BT) group, whereas 33 patients diagnosed with primary bladder cancer without a history of pelvic RT were classified into the bladder tumor (BT) group. The frequency of TERT promoter mutations was 35.7% and 63.6% in the RA-BT and BT groups, respectively (p = 0.112). Among the other characteristic mutations, FGFR3 and TP53 were frequently observed in both groups (FGFR3: RA-BT vs. BT, 14.3 vs. 42.4%; TP53: RA-BT vs. BT, 50 vs. 33.3%). Rare mutations in bladder cancer were more frequently observed in the RA-BT group, including ADGRB3 (28.6%), CBL (21.4%), TGM7 (21.4%), and BTK (14.3%). There were significantly more C → T substitutions in the RA-BT group than in the BT group. In our study, the genetic mutations in the RA-BT group had distinct features from those in the BT group.https://doi.org/10.1038/s41598-025-05149-z
spellingShingle Shogo Adomi
Kazuko Sakai
Yurie Kura
Marco A De Velasco
Saizo Fujimoto
Shingo Toyoda
Mamoru Hashimoto
Mitsuhisa Nishimoto
Eri Banno
Yoshitaka Saito
Koichi Sugimoto
Yujiro Hayashi
Takafumi Minami
Kazuhiro Yoshimura
Hirotsugu Uemura
Kazuto Nishio
Kazutoshi Fujita
Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers
Scientific Reports
title Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers
title_full Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers
title_fullStr Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers
title_full_unstemmed Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers
title_short Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers
title_sort comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers
url https://doi.org/10.1038/s41598-025-05149-z
work_keys_str_mv AT shogoadomi comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT kazukosakai comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT yuriekura comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT marcoadevelasco comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT saizofujimoto comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT shingotoyoda comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT mamoruhashimoto comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT mitsuhisanishimoto comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT eribanno comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT yoshitakasaito comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT koichisugimoto comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT yujirohayashi comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT takafumiminami comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT kazuhiroyoshimura comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT hirotsuguuemura comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT kazutonishio comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers
AT kazutoshifujita comparisonofgeneticmutationsinbladdercancersthatarosefollowingradiotherapyforprostatecancerwiththoseinprimarybladdercancers